



## Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

*Article 223-16 of the General Regulations of the Financial Markets Authority  
(AMF - Autorité des Marchés Financiers)*

**Lyon, France, September 8, 2023 6:00 pm CET – [MaaT Pharma](#) (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to improving survival outcomes for patients with cancer,** today published the number of shares comprising the share capital and the total number of voting rights (Article L. 233-8 of the French Commercial Code (Code de commerce) and Article 223-16 of the General Regulations of French Autorité des Marchés Financiers (AMF)) on August 31, 2023.

**Listing place:** Euronext Paris

**ISIN code:** FR0012634822

**Website:** [www.maatpharma.com](http://www.maatpharma.com)

Date	Total number of shares comprising the share capital	Total number of theoretical voting rights <sup>(1)</sup>	Total number of effective voting rights <sup>(2)</sup>
08/31/2023	11 592 999	11 592 999	11 574 849

*(1) In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.*

*(2) Effective voting rights correspond to the total number of voting rights that may be used at a General Meeting. The total number of effective voting rights is calculated without taking into account the shares with suspended voting rights.*

### **About MaaT Pharma**

MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint®, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations.

MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).



### **Forward-looking Statements**

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

### **Contacts**

#### **MaaT Pharma – Investor Relations**

Guillaume Debroas, Ph.D.  
Head of Investor Relations  
+33 6 16 48 92 50  
[invest@maat-pharma.com](mailto:invest@maat-pharma.com)

#### **MaaT Pharma – Media Relations**

Pauline Richaud  
Senior PR & Corporate  
Communications Manager  
+33 6 14 06 45 92  
[media@maat-pharma.com](mailto:media@maat-pharma.com)

#### **Trophic Communications – Corporate Communications**

Charlotte Spitz or Stephanie May  
+49 171 351 2733  
[maat@trophic.eu](mailto:maat@trophic.eu)